The company has developed an artificial intelligence-based drug discovery platform that uses few-shot learning and best-in-class AI methods for molecular representation, structure and ligand-based de novo design, and multiparameter optimization. This platform optimizes the development of drugs through predictive analytics and works with small and noisy datasets characteristic of low-throughput compound screens and late-stage lead optimization. By doing so, Valence Discovery enables pharmaceutical companies to reduce the time, design, and optimize novel ligands against a broad range of precision medicine targets.